MedTrace Logo

Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children

NCT05686863 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2023-08-21

No results posted yet for this study

Summary

To observe the sedative effect and safety of remiazolam combined with small dose of esketamine in painless bidirectional endoscopy in children, and to provide a more reasonable and safe sedative and analgesic regimen for children's gastrointestinal endoscopy.

Conditions

  • Drug Effect

Interventions

DRUG

Remimazolam

Remazolam for sedation in children undergoing bidirectional endoscopy

DRUG

Esketamine

Esketamine

DRUG

Propofol

Propofol

DRUG

remifentanil

remifentanil

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Hong Liu, Dr · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-18
Primary Completion
2023-07-07
Completion
2023-07-07

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05686863 on ClinicalTrials.gov